公开(公告)号：US11639351B2

公开(公告)日：2023-05-02

申请号：US17183401

申请日：2021-02-24

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: A61K31/4436 ,  A61K31/444 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/08

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20220265634A1

公开(公告)日：2022-08-25

申请号：US17668340

申请日：2022-02-09

Applicant: XENON PHARMACEUTICALS INC.

Inventor： Simon Neil PIMSTONE

IPC: A61K31/472 ,  A61P25/24

Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US11135214B2

公开(公告)日：2021-10-05

申请号：US16410851

申请日：2019-05-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Gregory N. Beatch

IPC: A01N37/00 ,  A61K31/215 ,  A01N37/12 ,  A01N37/44 ,  A61K31/24 ,  A01N25/00 ,  A61K31/472 ,  A61P25/08 ,  A61K9/00

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US11130726B2

公开(公告)日：2021-09-28

申请号：US16685335

申请日：2019-11-15

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Ivan William Hemeon ,  Brian Salvatore Safina ,  Daniel Sutherlin

IPC: C07C62/38 ,  C07C62/34 ,  C07C229/48 ,  C07D211/22 ,  C07C317/44 ,  C07C323/61 ,  C07C69/757 ,  A61P25/00 ,  A61P29/00 ,  A61P17/04 ,  C07C313/04

Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20210213009A1

公开(公告)日：2021-07-15

申请号：US17121305

申请日：2020-12-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： James Philip JOHNSON, JR. ,  Gregory N. BEATCH

IPC: A61K31/472 ,  A61K9/00 ,  A61P23/00

Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20210171516A1

公开(公告)日：2021-06-10

申请号：US17031348

申请日：2020-09-24

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Philippe BERGERON ,  Kristen BURFORD ,  Sultan CHOWDHURY ,  Christoph Martin DEHNHARDT ,  Thilo FOCKEN ,  Michael Edward GRIMWOOD ,  Abid HASAN ,  Kwong Wah LAI ,  Zhiguo LIU ,  Steven MCKERRALL ,  Teresa Phuongtram NGUYEN ,  Brian Salvatore SAFINA ,  Daniel SUTHERLIN ,  Tao WANG

IPC: C07D417/12 ,  C07D417/14 ,  A61P17/04 ,  C07D401/12 ,  C07D405/14 ,  C07D491/107

Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20210169839A1

公开(公告)日：2021-06-10

申请号：US17109937

申请日：2020-12-02

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy

IPC: A61K31/27 ,  A61K9/00 ,  A61K47/38 ,  A61K47/36 ,  A61K47/10 ,  A61K47/32

Abstract: Disclosed herein are immediate-release oral pharmaceutical formulations comprising a therapeutically effective amount of ezogabine and one or more pharmaceutically acceptable excipients for use in treating epilepsy and/or epileptic seizure disorders in a mammal, preferably a human, more preferably a child. Also disclosed are methods of using and making the immediate-release oral pharmaceutical formulations.

公开(公告)号：US20210093618A1

公开(公告)日：2021-04-01

申请号：US16677487

申请日：2019-11-07

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Jean-Christophe ANDREZ ,  Paul Robert BICHLER ,  Chien-An CHEN ,  Sultan CHOWDHURY ,  Shannon Marie DECKER ,  Christoph Martin DEHNHARDT ,  Thilo FOCKEN ,  Michael Edward GRIMWOOD ,  Ivan William HEMEON ,  Qi JIA ,  Jun LI ,  Zhiguo LIU ,  Daniel F. ORTWINE ,  Brian Salvatore SAFINA ,  Daniel SUTHERLIN ,  Tao SHENG ,  Shaoyi SUN ,  Andrew D. WHITE ,  Michael Scott WILSON ,  Alla Yurevna ZENOVA ,  Jiuxiang ZHU

IPC: A61K31/445 ,  C07D295/26 ,  A61K31/4015 ,  C07D211/22 ,  C07D233/68 ,  C07D305/08 ,  C07D205/12 ,  A61K31/4523 ,  C07D405/12 ,  C07D413/06 ,  C07D451/02 ,  C07D405/04 ,  C07D211/54 ,  C07D403/12 ,  C07D487/08 ,  C07D237/08 ,  C07D205/04 ,  C07D211/32 ,  A61K31/4412 ,  A61K31/415 ,  C07D401/04 ,  A61K31/337 ,  A61K31/495 ,  C07D211/60 ,  A61K31/4545 ,  C07D403/04 ,  C07D413/12 ,  C07D401/12 ,  C07D265/30 ,  C07D417/06 ,  C07D451/06 ,  C07D211/42 ,  A61K31/397 ,  C07F7/08 ,  C07D211/96 ,  C07D241/04 ,  C07D401/06 ,  C07D453/02 ,  C07D207/12 ,  C07D295/155

Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20210078947A1

公开(公告)日：2021-03-18

申请号：US16702286

申请日：2019-12-03

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Jean-Christophe ANDREZ ,  Philippe BERGERON ,  Paul Robert BICHLER ,  Sultan CHOWDHURY ,  Christoph Martin DEHNHARDT ,  Thilo FOCKEN ,  Wei GONG ,  Michael Edward GRIMWOOD ,  Abid HASAN ,  Ivan William HEMEON ,  Qi JIA ,  Brian Salvatore SAFINA ,  Shaoyi SUN ,  Michael Scott WILSON ,  Alla Yurevna ZENOVA

IPC: C07D207/16 ,  C07D403/12 ,  C07D413/14 ,  C07D221/22 ,  C07D401/12 ,  C07D413/12 ,  C07C235/52 ,  C07D205/04 ,  C07D277/06 ,  C07D209/02 ,  C07D305/08 ,  C07D401/14 ,  C07D231/06 ,  C07D403/04 ,  C07D403/14 ,  C07D409/06 ,  C07D417/12 ,  C07D451/02 ,  C07D263/04 ,  C07D263/26 ,  C07C235/42 ,  C07C235/54 ,  C07D265/30 ,  C07D207/08 ,  C07D207/10 ,  C07D207/22 ,  C07D209/52 ,  C07D209/54 ,  C07D211/20 ,  C07D211/38 ,  C07D211/60 ,  C07D213/69 ,  C07D401/10 ,  C07D405/10 ,  C07D471/08

Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10752623B2

公开(公告)日：2020-08-25

申请号：US16555983

申请日：2019-08-29

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson

IPC: C07D417/14 ,  A61P25/08 ,  C07C53/18 ,  C07D401/14 ,  C07D409/14

Abstract: This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.